First Choice Neurology

Alzheimer’s

World Alzheimer’s Day: Alzheimer’s, Dementia, and the Brain

Today is World Alzheimer’s Day. It’s a day to celebrate to create awareness about the disease and to reduce the stigmatization and lack of information surrounding dementia. While World Alzheimer’s Month offers a longer period of time for Alzheimer’s or dementia associations worldwide to raise awareness, World Alzheimer’s Day marks the focal point of the …

World Alzheimer’s Day: Alzheimer’s, Dementia, and the Brain Read More »

Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients

Biogen is providing its new Alzheimer’s drug Aduhelm free to some patients because of slow reviews by Medicare. There is a division among doctors about whether Aduhelm, also known as aducanumab, the $56,000-a-year drug helps patients. There is also uncertainty about reimbursement from Medicare. Aduhelm was approved by the U.S. Food and Drug Administration (FDA) …

Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients Read More »

First Florida Patient to Receive Biogen Aducanumab Infusion

Jeff Gelblum, MD, a board-certified neurologist with First Choice Neurology, the nation’s largest neurology practice, is scheduled to treat the first patient in Florida with Biogen’s Aducanumab (Aduhelm), a monthly infusion treatment for early-stage Alzheimer’s patients. The drug works to decrease amyloid plaque in the brain, which is a marker for Alzheimer’s disease. According to Dr. …

First Florida Patient to Receive Biogen Aducanumab Infusion Read More »

Alzheimer’s Patients and Holiday Gatherings

The holidays can be a stressful time, especially for families of a loved one diagnosed with Alzheimer’s disease. When a family member has dementia or Alzheimer’s disease, the family dynamic changes dramatically. Nowhere is this more evident than at holiday gatherings. Here are a few tips for families and caregivers: Prepare your family and friends. …

Alzheimer’s Patients and Holiday Gatherings Read More »

Biogen Seeks FDA Approval for New Alzheimer’s Drug

Biogen is planning to file for U.S. regulatory approval for its Alzheimer’s treatment aducanumab after data from more patients in two discontinued studies showed that the drug improved cognition at high doses. Patients who received aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation, and language, Biogen said. In March, …

Biogen Seeks FDA Approval for New Alzheimer’s Drug Read More »

June is Alzheimer’s and Brain Awareness Month

June is Alzheimer’s and Brain Awareness Month. Everyone who has a brain is at risk of developing Alzheimer’s disease (AD). There are 50 million people worldwide living with Alzheimer’s and other dementias. Alzheimer’s is not part of the normal aging process. It is a fatal disease that kills nerve cells in the brain and affects …

June is Alzheimer’s and Brain Awareness Month Read More »

Translate »